Acute liver failure

The liver does several jobs at once: it clears toxins from the blood, makes the proteins that let blood clot, stores and releases energy, and helps regulate blood pressure, fluid balance and immunity. In acute liver failure, a liver that was working normally stops doing those jobs over days to weeks — sometimes over hours. The two changes that define the condition are a measurable failure of clotting, seen on a blood test called the INR, and a change in brain function, called hepatic encephalopathy, which ranges from subtle drowsiness or personality change to deep coma.

Doctors distinguish acute liver failure from the far more common chronic liver diseases — cirrhosis, chronic hepatitis B, fatty liver disease — by the speed of onset and by the absence of pre-existing liver disease. The distinction matters because the two situations behave differently and are treated differently. A person with cirrhosis who deteriorates has usually been declining for months and is assessed for a planned transplant through a waiting list. A person with acute liver failure may have been entirely well two weeks earlier, and the decisions about their care — including whether to list them for an emergency transplant — are compressed into days.

The course of acute liver failure is genuinely unpredictable at the outset, which is why the condition is managed in hospital from the moment it is suspected. Some livers regenerate: the organ has a remarkable capacity to rebuild itself, and with intensive support — or, in paracetamol poisoning, with an antidote given early — many people recover completely without a transplant. Other livers pass a point of no return, and the signs that predict this are exactly what transplant teams watch for. Because nobody can promise at the start which course an individual will follow, the safest place to find out is a hospital that can do both: support a liver while it recovers, and transplant one that will not.

The terms fulminant hepatic failure and fulminant liver failure describe the same condition; older textbooks divide it by speed into hyperacute, acute and subacute forms. The labels matter less to a patient than the single practical rule they all share: sudden jaundice or confusion in a previously well person needs emergency assessment the same day.

How care is organised matters to families deciding what to do in the first hours. Most health systems concentrate acute liver failure in a small number of centres — the ones that combine liver intensive care with a transplant programme — and the practical consequence is that the FIRST hospital is rarely the LAST. A district emergency department stabilises, tests and telephones; the liver unit advises from the first call and accepts transfer when the picture warrants it. Families sometimes read transfer as deterioration; more often it is the system working as designed, moving the patient to the one building where every possible ending of this illness — recovery, transplant, or the decision between them — can be handled without another move.

Acute liver failure often begins with symptoms that feel like a viral illness, which is one reason it can be missed in its first days. Tiredness, nausea, loss of appetite and a general feeling of being unwell are common opening features. What separates it from a passing infection is what follows: the skin and the whites of the eyes turn yellow as bilirubin accumulates, urine darkens, and — the feature that defines the condition — thinking changes.

Hepatic encephalopathy, the brain component, is the symptom families usually notice before patients do. In its early grades it looks like poor concentration, unusual irritability, a reversed sleep pattern or small errors in familiar tasks. As it progresses, drowsiness deepens, speech slows, a characteristic flapping tremor of the outstretched hands may appear, and in the most severe grade the person cannot be woken. The grade of encephalopathy is one of the strongest signals a liver team uses when judging how dangerous an individual case is, which is why any confusion in a jaundiced person is treated as an emergency rather than observed at home. Families often become the crucial witnesses here: the patient with grade 1 encephalopathy typically insists they are fine, and it is the spouse who noticed the missed appointments, the odd word-choices, the afternoon sleeps, whose report moves the grading. Units take such collateral history seriously and say so — bringing a relative to the assessment is clinically useful, not merely supportive.

Bleeding and bruising reflect the second defining feature. The liver makes most of the body’s clotting factors, and as production fails, gums bleed with brushing, bruises appear from minor knocks, and blood tests show a rising INR. Swelling of the abdomen from fluid, breathlessness, and reduced urine output can follow as the failure begins to involve the circulation and the kidneys — acute liver failure is never only a liver disease, and its complications in other organs are what intensive care units manage hour by hour.

The commonest causes of acute liver failure differ from region to region, and the difference shapes both prevention and treatment. In much of Europe, North America and Australasia, the leading single cause is paracetamol (acetaminophen) poisoning — sometimes a deliberate overdose, sometimes an accidental one built up over several days of taking more than the labelled dose, often in combination products the person did not realise contained paracetamol. This cause matters disproportionately because it has a specific antidote, N-acetylcysteine, which is highly effective when given early. In much of Asia and Africa, acute viral hepatitis — hepatitis A, B and E — is the leading cause; hepatitis E is a particular danger in pregnancy.

Beyond those two large groups sit a long list of rarer causes that liver teams test for systematically, because several have specific treatments. Idiosyncratic drug reactions — an unpredictable response to a prescription medicine, a herbal remedy or a dietary supplement — account for a meaningful share of cases; the list of implicated substances is long, and an honest medication history, including anything bought without a prescription, is one of the most useful things a family can provide. Autoimmune hepatitis, in which the immune system attacks the liver, may respond to corticosteroids. Wilson’s disease, an inherited disorder of copper handling, can declare itself for the first time as liver failure in a young person. Budd–Chiari syndrome — clotting of the veins that drain the liver — has treatments of its own. Mushroom poisoning, classically with Amanita phalloides, remains a recognised cause wherever foraging is common. In pregnancy, two rare conditions — acute fatty liver of pregnancy and severe HELLP syndrome — cause liver failure that usually improves after delivery.

In a substantial minority of cases, no cause is ever identified despite full testing. These indeterminate cases are followed just as closely, because the absence of a label does not make the failure less dangerous — if anything, teams treat unexplained cases with extra caution.

Two cause-related nuances complete the picture. Timing matters as much as substance: a drug reaction may surface weeks after the medicine was started — or stopped — so the history sweep covers months, not days. And dose logic differs by mechanism: paracetamol injury is dose-dependent, while idiosyncratic reactions are not — a standard dose of the culprit can injure one person in fifty thousand and spare everyone else, which is why such reactions are unforeseeable and blame-free by their nature.

Anyone can develop acute liver failure, but several circumstances raise the risk or worsen the course. Regular heavy alcohol use lowers the threshold at which paracetamol injures the liver, as does prolonged fasting or malnutrition — a dangerous combination in someone unwell who has stopped eating but continues taking painkillers. Taking several paracetamol-containing products at once, or exceeding the labelled dose for several days running, causes a meaningful share of unintentional poisonings.

Unvaccinated travellers and residents in regions where hepatitis A and E circulate are at risk of the viral causes, with hepatitis E carrying particular danger for pregnant women. People with untreated or unmonitored chronic hepatitis B can suffer an acute flare severe enough to behave like acute liver failure, and certain cancer treatments and immunosuppressive drugs can reactivate hepatitis B in people who carried the virus silently — which is why screening before chemotherapy is standard. New prescription medicines, herbal preparations and bodybuilding or weight-loss supplements are all recognised triggers of idiosyncratic injury; the risk is small for any individual product but real across the category. A family history of Wilson’s disease, or liver disease in a previous pregnancy, are specific flags a doctor will ask about.

Two ladders matter in acute liver failure. The first is the grade of hepatic encephalopathy, which tracks how deeply the brain is affected and drives the urgency of every other decision. The second is the speed of onset — the interval from first jaundice to first confusion — which, counterintuitively, carries prognostic information: the very fastest presentations often have a better chance of spontaneous recovery than the slower, smouldering ones.

The diagnosis itself rests on three findings assessed together: evidence of severe liver injury on blood tests, impaired clotting measured by the INR, and any degree of encephalopathy, in a person without known chronic liver disease. Everything else in the work-up serves two purposes — finding the cause, because several causes have specific treatments, and measuring how far the failure has spread into other organ systems.

The cause hunt is systematic. Blood is tested for paracetamol level and for the viral hepatitides A, B, C and E; for the autoantibodies of autoimmune hepatitis; for caeruloplasmin and copper where Wilson’s disease is possible; and for pregnancy where relevant. A careful history of every medicine, remedy and supplement taken in the preceding months is gathered from the patient if they can give it, and from family if they cannot. An ultrasound scan with Doppler assessment of the hepatic veins looks for Budd–Chiari syndrome and for evidence of pre-existing cirrhosis, which would change the diagnosis entirely. A liver biopsy is occasionally used when the cause remains unclear and the answer would change management, but it is not routine — clotting failure makes biopsy hazardous, and the result rarely changes the immediate decisions.

The severity work-up repeats on a cycle measured in hours rather than days: INR and other clotting measures, kidney function and urine output, blood glucose (which can fall dangerously as the liver’s stores fail), lactate, ammonia, and arterial blood gases. These are the numbers that feed the prognostic assessments — including the King’s College criteria discussed below — on which the transplant decision turns. A person with acute liver failure can expect blood tests several times a day; each round is genuinely informative, because the trajectory matters more than any single value.

What a family can contribute to this phase is more useful than most realise: the exact names and doses of every medicine, remedy and supplement in the house; the timing of the first symptoms, however trivial they seemed; any history of foraged food, new prescriptions, herbal teas or weight-loss products; and previous blood test results from routine check-ups, which establish that the liver really was normal before. In a disease where the cause changes the treatment and the timeline feeds the prognostic scores, a shoebox of medicine packets and an old lab printout have altered management more than once.

Families of patients with acute liver failure hear a stream of laboratory values. These are the ones quoted most often, what each measures, and why it matters. None of them is meaningful in isolation — teams read the direction of travel across repeated tests.

Acute liver failure endangers organs far beyond the liver, and most of the intensive care effort goes into the complications rather than the liver itself. The most feared is swelling of the brain — cerebral oedema — which accompanies the deeper grades of encephalopathy, particularly in the fastest-onset cases. It is managed with careful control of the patient’s position, breathing, sodium levels and sedation, and it is the main reason a deteriorating patient is moved to intensive care before they seem, to a family’s eye, desperately ill.

Infection is the second constant threat. The failing liver weakens immune defences precisely when drips, catheters and ventilators create routes in, and infection can both mimic and worsen encephalopathy. Many units monitor for it continuously and treat on suspicion. Kidney failure accompanies a large fraction of severe cases — from the same toxin, from the disturbed circulation, or both — and temporary dialysis is common in intensive care; the kidneys usually recover if the liver does. Bleeding, despite the alarming INR, is less frequent than the numbers suggest, because the liver fails to make clotting and anti-clotting proteins alike; teams generally correct clotting only for procedures or active bleeding. Low blood pressure, low blood sugar and metabolic disturbances complete the picture — each individually manageable, collectively the reason this condition is managed in an intensive care unit rather than on a ward.

Two further complications earn mention because families ask about them. Pancreatitis accompanies some severe cases — one reason abdominal symptoms are imaged rather than assumed. And aplastic anaemia — marrow failure — follows a small fraction of hepatitis-associated liver failure, usually in young men, weeks after the liver event; it is rare, treatable, and the reason follow-up blood counts continue after apparent recovery from that particular cause.

Much acute liver failure is preventable, and the levers are unglamorous. Paracetamol is safe at labelled doses for almost everyone — the danger lives in doubling up. Checking the label of every cold-and-flu remedy, sleep aid and combination painkiller for paracetamol content, never taking more than one paracetamol-containing product at a time, and respecting the maximum daily dose even when pain is poorly controlled would prevent a large share of the accidental poisonings that reach liver units. Anyone who realises they may have exceeded safe doses — even without symptoms — should seek medical assessment the same day, because the antidote works best early, before any symptom appears.

Vaccination against hepatitis A and B is effective and widely available; for travellers to regions where the viruses circulate, and for everyone in higher-risk groups, it removes two causes outright. Pregnant women should be careful with food and water hygiene where hepatitis E is present. People with chronic hepatitis B need monitoring rather than heroics — an acute flare is far less likely under specialist follow-up, and anyone starting chemotherapy or strong immunosuppression should be screened for hepatitis B first, which is standard practice precisely because reactivation is preventable with antiviral cover.

With herbal remedies and supplements, honest ignorance is the enemy: products are unregulated in many markets, and “natural” is not a safety claim. Mentioning every product to a doctor — and stopping them when unexplained tiredness, nausea or jaundice appears — is the practical protection. Foragers should treat wild mushrooms with the seriousness the emergency departments of every foraging region have learned to.

Households can also prepare for the version of this page nobody plans to need. Keeping medicines in original packaging (so an overdose can be quantified), storing paracetamol out of teenagers’ easy reach in difficult seasons, knowing the national poisons-information number, and treating any deliberate overdose as a same-day medical event even when the person feels well — these unglamorous habits shorten the interval this disease most punishes: the one between ingestion and antidote.

Treatment happens on three fronts at once, and which front dominates depends on the cause and the severity. The first front is cause-specific treatment. Paracetamol poisoning is treated with N-acetylcysteine, an antidote that replenishes the liver’s capacity to neutralise the toxic by-product; given early it is remarkably effective, and many units also use it in non-paracetamol acute liver failure. Acute hepatitis B is treated with antiviral tablets. Autoimmune hepatitis may respond to corticosteroids. Amanita mushroom poisoning has its own protocols. Budd–Chiari syndrome may be treated by restoring the blocked drainage. Pregnancy-related liver failure is treated by delivering the baby. This is why the cause hunt runs alongside resuscitation rather than after it.

The second front is organ support: the intensive care work of keeping the patient alive while the liver decides whether it will recover. That means airway protection and ventilation in deeper encephalopathy, drugs to support blood pressure, glucose infusions, temporary dialysis for failing kidneys, meticulous infection surveillance, and the neurological care that guards against brain swelling. There is no machine that replaces a liver the way dialysis replaces kidneys; various liver-support devices have been studied, and none has yet earned a routine role. The liver’s own regenerative capacity, supported well, is the recovery route for the majority.

The third front is transplantation, held ready in parallel rather than in sequence. From early in a severe case, the team is scoring the patient against listing criteria, contacting a transplant centre, and assessing fitness for surgery — so that if the moment comes, no time is lost. The decision is genuinely difficult in both directions: transplanted too early, a person loses a liver that would have recovered and gains a lifetime of immunosuppression; listed too late, they may become too ill for surgery. This is the judgement the prognostic criteria exist to support.

Supportive care has its own craft, refined in specialist units: feeding is maintained — often by tube — because a failing liver empties the body’s energy stores within hours; sedation is used sparingly and deliberately, since it can mask the encephalopathy grades the team is tracking; medicines cleared by the liver are re-dosed or stopped; and stress-ulcer prevention, careful glucose infusion and early physiotherapy each defend against a specific, predictable complication. None of these is dramatic; together they are much of why survival in specialist units has improved even before any transplant is considered.

For relatives, two questions are always legitimate and worth asking early: is this patient in — or in contact with — a centre that performs liver transplantation, and what would trigger either transfer or listing? A clear answer to both is a mark of a well-run pathway; a vague one is a reason to ask again.

Transplantation is considered when the evidence says the liver is unlikely to recover in time. The most widely used decision aids are the King’s College criteria, which combine different signals for paracetamol and non-paracetamol causes — severe acidosis or the triad of advanced encephalopathy, marked clotting failure and kidney failure after paracetamol; and combinations of age, cause, jaundice-to-encephalopathy interval, INR and bilirubin in other causes. Meeting the criteria does not make transplantation automatic, and not meeting them does not make it impossible; they are the structured starting point for a decision that also weighs fitness for surgery, active infection, and — hardest of all — whether irreversible brain injury has already occurred.

Because acute liver failure moves fast, patients who meet the threshold are listed in most systems as super-urgent: they go to the top of the national queue, and a donor organ is sought within days. This is one of the clearest illustrations of a principle that applies across transplantation — allocation follows medical urgency under national rules. It cannot be bought, and no reputable service anywhere offers to sell a place in it. The listing conversation itself follows a rhythm families can anticipate: the transplant team assesses, presents to the national super-urgent scheme with the criteria evidence, and — once accepted — offers can come at any hour, which is why the patient is kept fasted and theatre-ready. Declining an organ on quality grounds and waiting for the next is part of the craft, not a setback; the team explains each decision as it happens. For international patients, the practical meaning is blunt: acute liver failure is treated in the country where it happens. Travelling with the condition is dangerous and usually impossible; what a platform like this one can honestly help with is the planned transplantation that may follow survivable chronic disease — see the liver transplant and living donation guides — not the emergency itself.

A note on living donation: in some countries, an urgent living-donor liver transplant — usually from a close relative donating part of their liver — is performed for acute liver failure when no deceased-donor organ is available in time. It compresses a donor evaluation that normally takes weeks into a very short window, and centres that offer it apply strict safeguards, because the donor’s safety rules are not relaxed for the recipient’s emergency.

The outlook in acute liver failure has improved substantially over the decades, for two reasons that reinforce each other: intensive care has become better at keeping patients alive through the dangerous days, and transplantation reliably rescues many of those whose livers cannot recover. Outcomes differ sharply by cause — paracetamol-related and hepatitis A–related failure carry a comparatively high chance of spontaneous recovery, while subacute, drug-induced and indeterminate failure more often end in transplantation — and by the depth of encephalopathy reached before treatment began.

For those who recover without a transplant, the liver’s regeneration is usually complete: most people return to normal liver function and normal life, with follow-up focused on whatever caused the failure — completing an autoimmune treatment course, managing hepatitis B, or the psychological care that must follow a deliberate overdose. For those who receive a transplant, the outlook is that of liver transplantation generally: a major operation followed by lifelong immunosuppression, structured follow-up, and for the large majority a return to work, family life and travel. Precise survival figures vary by country, era and cause; the honest generalisation is that both recovery and transplantation now offer genuinely good outcomes to patients who reach specialist care in time — which returns this page to the message it started with. Speed of presentation is the variable a patient and family control.

Recovery, by either route, deserves its own sentence. Survivors of acute liver failure — with their own liver or a transplanted one — commonly describe a long tail: months of fatigue, rebuilt strength, and, where an overdose or a missed diagnosis began the story, psychological work that matters as much as the biochemistry. Follow-up typically runs closely for the first year and then relaxes; driving, work and travel resume on the team’s advice rather than a fixed calendar; and pregnancy after recovery is usually possible, planned with the specialists involved. The condition that nearly ended everything usually leaves, in the end, surprisingly little day-to-day residue — a fact worth holding onto in the intensive care weeks, when it is hardest to believe.